Premium
OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R‐CHOP AND WERE NOT CANDIDATES FOR HIGH‐DOSE THERAPY AND ASCT ‐ PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG‐8)
Author(s) -
PaszkiewiczKozik E.,
Michalski W.,
Taszner M.,
KnopińskaPosłuszny W.,
MordakDomagała M.,
Najda J.,
Borawska A.,
RomejkoJarosińska J.,
Chełstowska M.,
Świerkowska M.,
DąbrowskaIwanicka A.,
Malenda A.,
DruzdSitek A.,
Konecki R.,
Kuniega B.,
Osowiecki M.,
Ostrowska B.,
Szpila T.,
DomańskaCzyż K.,
Szymański M.,
Targoński Ł.,
Poplawska L.,
Kotarska M.,
Giebel S.,
Lange A.,
Pluta A.,
Warzocha K.,
Zaucha J.,
Rymkiewicz G.,
Walewski J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.111_2631
Subject(s) - medicine , ofatumumab , rituximab , oncology , clinical endpoint , diffuse large b cell lymphoma , febrile neutropenia , chemotherapy regimen , progression free survival , interim analysis , regimen , surgery , neutropenia , chemotherapy , clinical trial , lymphoma